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Background: Nucleostemin is a GTPase residing in the nucleolus that is considered to be an important cancer
stem/progenitor cell marker protein due to its high expression levels in breast cancer stem cells and its role in
tumor initiation of human mammary tumor cells. It has been proposed that nucleostemin may represent a
valuable therapeutic target for breast cancer; however, to date evidence supporting the cellular mechanism has
not been elucidated.
Results: Expression of exogenous HER2, a member of the EGF receptor gene family, in the human MCF-10AT
preneoplastic mammary epithelial cell line, formed a new breast cancer cell line, 10AT-Her2, which is highly
enriched in cells with stem/progenitor cell-like character. 10AT-Her2 cells display a CD44+/CD24-/low phenotype with
high levels of the cancer stem/progenitor cell marker proteins nucleostemin, and active aldehyde dehydrogenase-1
(ALDH-1). The overall expression pattern of HER2 protein and the stem/progenitor cell marker proteins in the
10AT-Her2 cell population is similar to that of the luminal HER2+ SKBR3 human breast cancer cell line, whereas both
MCF-7 and MDA-MB-231 cells display reduced levels of nucleostemin and no detectable expression of ALDH-1.
Importantly, in contrast to the other well-established human breast cancer cell lines, 10AT-Her2 cells efficiently form
tumorspheres in suspension cultures and initiate tumor xenograft formation in athymic mice at low cell numbers.
Furthermore, 10AT-Her2 cells are highly sensitive to the anti-proliferative apoptotic effects of indole-3-carbinol
(I3C), a natural anti-cancer indole carbinol from cruciferous vegetables of the Brassica genus such as broccoli and
cabbage. I3C promotes the interaction of nucleostemin with MDM2 (murine double mutant 2), an inhibitor of the
p53 tumor suppressor, and disrupts the MDM2 interaction with p53. I3C also induced nucleostemin to sequester
MDM2 in a nucleolus compartment, thereby freeing p53 to mediate its apoptotic activity. Small interfering RNA
knockdown of nucleostemin functionally documented that nucleostemin is required for I3C to trigger its cellular
anti-proliferative responses, inhibit tumorsphere formation, and disrupt MDM2–p53 protein–protein interactions.
Furthermore, expression of an I3C-resistant form of elastase, the only known target protein for I3C, prevented I3C
anti-proliferative responses in cells and in tumor xenografts in vivo, as well as disrupting the I3C-stimulated
nucleostemin–MDM2 interactions.
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Conclusions: Our results provide the first evidence that a natural anti-cancer compound mediates its cellular and
in vivo tumor anti-proliferative responses by selectively stimulating cellular interactions of the stem/progenitor
cell marker nucleostemin with MDM2, which frees p53 to trigger its apoptotic response. Furthermore, our study
provides a new mechanistic template that can potentially be exploited for the development of therapeutic
strategies targeted at cancer stem/progenitor cells.
Keywords: nucleostemin, cancer stem/progenitor cell marker, indole-3-carbinol, elastase signaling, nucleostemin–
MDM2 interaction, anti-proliferative response in breast cancer cell, tumor xenograft, tumorsphereBackground
The heterogeneity of human breast cancers results from
subpopulations of stem/progenitor cells that possess the
capacity for multi-lineage differentiation, and the ability
to self-renew and initiate the formation of tumors [1-7].
It has been proposed that the acquired phenotypes of
cancer stem cell populations, which constitute approxi-
mately 1% to 5% of the cells in primary breast tumors [1],
can direct the development of therapy-resistant tumors
and relapse of the disease, which significantly influences
the effectiveness of a therapeutic strategy [8,9]. Therefore,
a critical issue in cancer treatment is the identification of
anti-cancer agents that can directly target cancer stem
cells to prevent their self-renewal and/or tumor plasticity.
However, an experimental constraint that has limited the
characterization of stem cell targeted molecules is the
low number of cells that can be isolated from stem cell
populations enriched in vitro in tumorspheres [6,10], or
enriched in side-populations of tumor-initiating cells iso-
lated by flow cytometry from primary tumors [6,11,12].
Furthermore, once cultured in vitro, the in vivo isolated
stem cell populations can lose their stem cell character
and/or viability.
The orphan epidermal growth factor (EGF) receptor
gene family member HER2 (human epidermal growth
factor receptor-2) is associated with an enhancement of
stem/progenitor cell population levels in populations of
either normal mammary epithelial cells or certain cancer
cell lines [12,13]. Signaling by HER2 is highly associated
with aggressive metastatic forms of breast cancer [14,15],
and the gene is amplified in 20% to 30% of all human
breast cancers [16]. Expression of exogenous HER2 in
normal mammary stem cell populations generated hyper-
plastic lesions when transplanted in vivo [13], and in
breast cancer cells HER2 expression enhanced the occur-
rence of side-populations of tumor-initiating cells of the
luminal subtype and is clinically correlated with cancer
stem cell populations [12,13,17]. By expressing exogenous
HER2 in the MCF-10AT cell line, a well-established model
of human mammary epithelial preneoplasia [18], we
generated a new breast cancer cell line, denoted as
10AT-Her2, which is highly enriched with cells that dis-
play several cancer stem/progenitor cell-like properties.MCF-10AT cells were originally chosen as the starting
cell population for our study because of the intrinsic
low incidence of tumor formation [18-20] and the lack
of any cancer stem cell-like characteristics. In xenografts
of immunocompromised mice, a majority of MCF-10AT
cells will manifest into normal-appearing ducts; however,
a small percentage will displays lesions ranging from atyp-
ical hyperplasia to invasive carcinoma [18-20]. It is these
qualities that made the parent MCF-10AT cells an ideal
candidate system for studying the development of breast
cancer via cancer stem/progenitor cells. Cell populations
enriched with breast cancer stem cells can be identified by
expression of specific sets of marker proteins such as
nucleostemin and aldehyde dehydrogenase-1 (ALDH-1),
which are associated with maintenance and self-renewal
properties [21-24], and by their CD44+/CD24-/low pheno-
type [21]. We observed that the 10AT-Her2 cell popula-
tion, but not the corresponding 10AT-Neo transfection
control cells, express high levels of nucleostemin and
active ALDH-1 in the context of a CD44+/CD24-/low
phenotype, and are able to form tumors xenografts effi-
ciently in vivo in athymic mice and form tumorspheres in
suspension cultures at limiting cell dilutions. The 10AT-
Her2 cell system provided the experimental opportunity
directly to test the hypothesis that cellular components
that help define the cancer stem/progenitor character,
such as nucleostemin, can confer selective responsiveness
of anti-cancer compounds to target breast cancer stem/
progenitor populations.
Indole-3-carbinol (I3C), a natural indole carbinol pro-
duced from the hydrolysis of glucobrassicinin, is found
in cruciferous vegetables of the Brassica genus, such as
broccoli and cabbage, and is a promising anti-cancer
compound [25-29]. I3C treatment activates distinct sets
of anti-proliferative signaling cascades in a wide range of
human breast cancer cells [25,30-40], inhibits the in vivo
growth of human breast cancer cell-derived tumor xeno-
grafts [34], and reduces tumor metastasis and breast
cancer cell migration [35,41]. Clinical trials have con-
cluded that ingested I3C possesses anti-cancer effects in
human populations, has beneficial effects on estrogen
metabolism [42], and, based on cytotoxicity studies,
patients can receive as high as 800 mg/kg/day of I3C
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to note that the functional intracellular concentration of
I3C is significantly lower than the treated amount in
in vitro and in vivo studies because in cell culture stud-
ies only approximately 0.3% of extracellular I3C enters a
cell [46].
A key advance in understanding the molecular mech-
anism of the anti-cancer actions of indole carbinols is
our discovery that I3C and its highly potent derivative 1-
benzyl-I3C [47], but not the natural I3C dimerization
product 3,3'-dimethylindolylmethane (DIM), act as dir-
ect noncompetitive inhibitors of elastase enzymatic ac-
tivity, the first such identified target protein for I3C
[33,34,48]. Intriguingly, a high level of elastase activity
has been associated with late stage breast cancer [49]. In
silico simulations that model I3C interactions with the
crystallographic structure of elastase, uncovered a critical
interaction site for I3C (and 1-benzyl-I3C) that provided
the experimental foundation for generating a truncated
form of elastase that is enzymatically active but resistant to
inhibition by either I3C or 1-benzyl-I3C [48]. Using this
unique reagent, we demonstrate that I3C triggers an
elastase-dependent anti-proliferative response in the 10AT-
Her2 breast cancer cell population by promoting nucleos-
temin to interact with and sequester the murine double
mutant 2 (MDM2) protein into the nucleolus, thereby
allowing the p53 tumor suppressor protein to escape from
the MDM2 inhibition of apoptotic activity. Our study has
uncovered new mechanistic insights into how the cancer
stem/progenitor cell-associated component nucleostemin
is directly involved in an anti-proliferative cell signaling
pathway triggered by I3C, a natural anti-cancer molecule.
Results
Expression of exogenous HER2 in preneoplastic mammary
epithelial cells induces a stable cancer stem/progenitor
cell-like phenotype
To generate a mammary epithelial cancer cell system
highly enriched with tumor-initiating cells that express
high levels of nucleostemin, preneoplastic MCF-10AT
human mammary epithelial cells [18-20] were stably
transfected with either the CMV-HER2 expression vector
containing the neomycin resistance gene, or the control
CMV-neomycin resistance gene vector forming 10AT-
Her2 and 10AT-Neo cells, respectively. Western blot
analysis demonstrated that 10AT-Her2 cells expressed
significantly higher levels of HER2 compared to the
control 10AT-Neo cell line (Figure 1A, top panel). I3C-
treated conditions will be discussed in a later section.
Western blots also demonstrated that the 10AT-Her2
cell population is highly enriched with cells that express
significantly elevated levels of nucleostemin, ALDH-1 and
CD44, and the maintenance of nearly undetectable levels
of CD24 (Figure 1A), which is a phenotype associated witha cancer stem cell/progenitor cell-like character. In con-
trast, the control 10AT-Neo cell population maintained
the same phenotype as the starting preneoplastic MCF-
10AT cells with nearly undetectable to low levels of CD44,
CD24, ALDH-1 and nucleostemin.
To determine the percentage of cells within the 10AT-
Her2 cell population that display stem/progenitor cell-
like marker proteins, the levels of cell surface-associated
CD44 and CD24 were quantified by flow cytometry using
antibodies specific for either CD44 or CD24. As shown in
Figure 1B, greater than 98% of 10AT-Her2 cells in the
population express high levels of CD44 compared to the
background levels observed with control transfected
10AT-Neo cells. The level of CD24 remained low in both
cell lines and was expressed in less than 2% of the cell
population (Figure 1B). An ALDEFLUOR assay verified
that greater than 88% of the ALDH-1 in the 10AT-Her2
cell population is enzymatically active while less than 1%
of the ALDH-1 in 10AT-Neo cells was active (Figure 1C).
The elevated level of ALDH-1 activity in the 10AT-Her2
cell population is consistent with previous studies showing
that the subpopulations within normal and cancer human
mammary epithelial cells with increased ALDH-1 have
stem/progenitor cell-like properties [24]. The phenotype
of the overall 10AT-Her2 cell population, which displays
high levels of nucleostemin and active ALDH-1 in a
CD44+/CD24–/low phenotype background, has remained
stable after continuous culturing of this cell line for more
than 6 months over many cell generations.
The in vitro formation of tumorspheres in cell suspen-
sion cultures is considered a cellular property of cancer
stem/progenitor cells within a cell population that is pre-
dictive of tumor initiation properties [6,23]. 10AT-Her2
and 10AT-Neo cells were therefore cultured at low density
(approximately 4,000 cells/ml) in cell suspensions, and
in vitro tumorsphere formation was monitored visually for
6 days. As shown in Figure 2A, 10AT-Her2 cells began to
form tumorsphere-like structures within 2 days of culture
and by 6 days the cells formed completed tumorspheres.
In contrast, the control 10AT-Neo cells failed to form
tumorspheres and remained dispersed in small cell aggre-
gates. The tumorsphere-forming efficiency of 10AT-Her2
cells was compared to that of two luminal subtype tumori-
genic breast cancer cell lines, SKBR3 and MCF-7, which
differ in their expression of HER2 [50]. The Western blot
insert in Figure 2B shows that SKBR3 and 10AT-Her2
cells produce approximately the same levels of HER2 pro-
tein, whereas MCF-7 cells produce significantly lower
levels of HER2. By culturing increasing numbers of cells
in suspension, the 10AT-Her2 cells were more than ten-
fold more efficient in their tumorsphere-forming capabil-
ity compared to either SKBR3 or MCF-7 breast cancer
cells (Figure 2B). For example, the number of tumor-
spheres formed from 2,000 10AT-Her2 cells was observed
Figure 1 Expression of cancer stem/progenitor cell-like marker proteins in 10AT-Her2 and 10AT-Neo cells. (A) Cultured HER2-expressing
10AT-Her2 cells and empty vector transfected 10AT-Neo control cells were treated with or without 200 μM I3C for 48 hours. Production of HER2,
CD44, CD24, ALDH-1, nucleostemin (NS) and actin protein were determined by Western blot analysis of electrophoretically fractionated total cell
extracts. (B) Cell surface expression of CD44 and CD24 in 10AT-Her2 cells and 10AT-Neo cells was quantified by flow cytometry of 500,000 cells in
triplicate independent cell cultures. (C) ALDH-1 activity was quantified in 10AT-Her2 and 10AT-Neo cells by ALDEFLUOR assay as described in the
Methods section. ALDH-1, aldehyde dehydrogenase-1; HER2, human epidermal growth factor receptor-2; NS, nucleostemin.
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assayed. Also, because SKBR3 and 10AT-Her2 express
similar levels of HER2 protein, the ability of 10AT-Her2
cells to form tumorspheres cannot be attributed only to
the high level of exogenous HER2.
To compare the expression of cancer stem/progenitor
cell-like marker protein in the 10AT-Her2 cell popula-
tion with other well-established human breast cancercell lines, protein levels of nucleostemin, CD44, ALDH-1
and CD24 were assessed in 10AT-Neo, 10AT-Her2,
MCF-7, MDA-MB-231 and SKBR3 cells (Figure 2C). As
mentioned above, MCF-7 and SKBR3 cells represent
two distinct luminal subtypes, whereas, MDA-MB-231
cells represent a triple negative basal subtype. Western
blot analysis indicated that 10AT-Her2 cells and SKBR3
cells express relatively comparable levels of HER2,
Figure 2 Tumorsphere formation efficiency in cell suspension cultures, expression of stem/progenitor cell marker proteins and
proliferation of breast cancer cells. (A) 10AT-Her2 and 10AT-Neo cells were plated at a density of 4,000 cells per well in serum-free
non-adherent suspension cultures as described in the Methods section. At the indicated days in culture, tumorsphere formation was assessed
visually by phase microscopy. Scale bar represents 50 μm. (B) 10AT-Her2 and 10AT-Neo cells as well as the SKBR3 and MCF-7 human breast
cancer cell lines were incubated at the indicated cell densities. Tumorsphere formation efficiency was quantified after 6 days in culture under
non-adherent conditions. The presented values are an average of three independent experiments. The gel inserts are Western blots showing
relative levels of HER2 protein expression and actin controls from electrophoretically fractionated total cell extracts of MCF-7, SKBR3 and
10AT-Her2 cells. (C) Cultured 10AT-Neo, 10AT-Her2, MCF-7, MDA-MB-231 and SKBR3 cells were harvested, total cell extracts electrophoretically
fractionated and the levels of expressed HER2, CD44, CD24, ALDH-1, nucleostemin (NS) and actin protein determined by Western blots. (D) To
examine the effects of I3C on cell proliferation, 10AT-Neo, 10AT-Her2, SKBR3, MCF-7 and MDA-MB-231 cells cultured in a 24-well plate were
treated with 200 μM I3C for the indicated times and the cell number quantified as described in the Methods section. ALDH-1, aldehyde
dehydrogenase-1; HER2, human epidermal growth factor receptor-2; NS, nucleostemin.
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tumorsphere-forming properties of SKBR3 cells are
significantly less efficient than that of 10AT-Her2 cells
(Figure 2B). Densitometric analysis of the Western blots
show that both MCF-7 cells and MDA-MB-231 breast
cancer cells express approximately 30% of the levels of
nucleostemin compared to either 10AT-Her2 or SKBR3
cells. The production of ALDH-1 was not detected in ei-
ther MCF-7 cells or MDA-MB-231 cells, whereas, MCF-
7 cells also do not express CD44. These results showthat even though well-established breast cancer cell lines
express specific stem/progenitor cell-like protein markers,
the 10AT-Her2 cell population can be considered to have
a more enhanced ‘stemness’ character because of its highly
efficient tumorsphere-formation property (Figure 2B), and
as discussed in later sections, its ability to form tumor xe-
nografts at low cell numbers in athymic mice.
The anti-proliferative effects of I3C were analyzed in
10AT-Her2 cells and 10AT-Neo cells in comparison to
MCF-7, MDA-MB-231 and SKBR3 breast cancer cells,
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natural indole carbinol compound [31-34,38-41]. Cells
were treated with 200 μM I3C, which is the optimal con-
centration for its anti-cancer effects in breast cancer cell
lines [32-34,39,41], and the number of cells in each cell
culture well were quantified throughout 48 hours. As
shown in Figure 2D, of the tested cell lines, 10AT-Her2
cells were the most sensitive to the cytotoxic effects of
I3C and displayed a near complete loss of cell prolifera-
tion after 48 hours of treatment with I3C. In contrast,
the transfection control 10AT-Neo cells were only mildly
sensitive to the cytotoxic effects of I3C. Each of the
three well-established breast cancer cell lines show simi-
lar levels of sensitivity to I3C, although the effect was
not as efficient as observed in the 10AT-Her2 cells.
I3C disrupts in vitro 10AT-Her2 cell tumorsphere
formation and in vivo tumor xenograft growth
The potential I3C inhibition of the in vitro formation of
10AT-Her2 cell tumorspheres was examined in cell sus-
pensions that were treated for 6 days with or without
200 μM I3C. Analysis by light microscopy revealed that
I3C completely prevented the in vitro formation of tumor-
spheres (Figure 3A). Only approximately 0.3% of I3C en-
ters breast cancer cells from the cell culture medium [46],
so the functional intracellular concentration of this indole
carbinol compound is significantly lower than that added
to the cell cultures. Quantification of the efficiency of
10AT-Her2 cell tumorsphere formation demonstrated that
I3C had strong inhibitory effects on this cancer stem/pro-
genitor cell-like process (Figure 3A, bar graphs). This in-
hibitory effect on in vitro 10AT-Her2 cell tumorsphere
formation was specific for I3C-based indole carbinol
compounds because the highly potent I3C derivative
1-benzyl-I3C [47] inhibited tumorsphere formation by
98% at significantly lower concentrations than I3C;
whereas, the inactive indole carbinol compound trypto-
phol, which is structurally similar to I3C [47], had no
effect on tumorsphere formation (Figure 3B). Other
phytochemicals that display strong anti-proliferative re-
sponses in a variety of breast cancer cell lines, such as
the natural I3C dimer, DIM [28], and artemisinin [51],
had no effect on 10AT-Her2 cell tumorsphere formation
(Figure 3B). Therefore, the disruption of tumorsphere
formation in cell suspension cultures is a property spe-
cific to I3C and its highly potent derivative compared to
other phytochemicals that can target breast cancer cells.
The in vivo tumor-initiating capability of the 10AT-
Her2 cell line in comparison to control 10AT-Neo cells
was analyzed by formation of tumor xenografts in NIH
III athymic nude mice. When 3 million control 10AT-Neo
cells were injected into the athymic mice, this cell line dis-
played a 20% to 25% tumor efficiency, which is consistent
with sporadic events associated with the preneoplasticnature of the parental MCF-10AT cell line (Figure 3C). In
contrast, 10AT-Her2 cells were highly efficient in the abil-
ity to form tumor xenografts in athymic mice. In a series
of limiting dilution studies, injection of 300,000 10AT-
Her2 cells form tumor xenografts at nearly 100% effi-
ciency (Figure 3C) and are capable of tumor initiation
when injections are carried out with as few as 20,000 cells
(data not shown). The ability of 10AT-Her2 cells to form
tumor xenografts in vivo is tenfold more efficient than
that reported for highly tumorigenic human breast cancer
cell lines such as MCF-7, MDA-MB-231 and SKBR3,
which require approximately 2 million cells for tumor xe-
nografts to be observed [52].
To assess the in vivo effects of I3C on the growth of
10AT-Her2-cell-derived tumor xenografts, 300,000 10AT-
Her2 cells were injected into NIH III athymic mice and
the resulting tumors were first allowed to grow to an aver-
age volume of approximately 100 mm3. The mice were
then injected subcutaneously with either I3C (300 mg/kg
body mass) or with the dimethyl sulfoxide (DMSO) ve-
hicle control over 19 days. In vehicle-control-treated ani-
mals, the 10AT-Her2 cell tumor xenografts showed robust
growth (Figure 3D). The concentration of I3C used for the
mice injections is approximately equivalent to the 200 μM
I3C used to treat the cultured cell lines. Also, in phase 1
clinical trials, women have been given as high a dose as
800 mg I3C per day with high tolerability [43-45], suggest-
ing that relatively high doses of I3C can be tolerated with-
out any adverse side effects. In the absence of I3C, the
resulting tumor xenografts displayed highly concentrated
gross tumor vascularization and were dense (Figure 3D,
micrograph insert), consistent with the rapid growth of
cells within the tumor. I3C strongly suppressed the
growth of 10AT-Her2 cell-derived tumor xenografts
(Figure 3D), and the resulting tumors appeared less vas-
cularized and much smaller in size (Figure 3D, micro-
graph insert). The texture of the residual tumors from
I3C-treated mice was pliable, consistent with reduced
cell density in the xenografts. Coupled with the fact that
10AT-Her2 cells are ten times more efficient at forming
tumorspheres in vitro (Figure 2B), our in vivo results
strongly suggest that the 10AT-Her2 cell population is
highly enriched with cancer stem/progenitor-like cells
with an efficient tumor-initiation capability.
I3C induces a p53-dependent apoptotic response and
promotes the interaction of the stem cell marker protein
nucleostemin with the MDM2 in 10AT-Her2 cells
To assess the anti-proliferative and apoptotic effects of
I3C, 10AT-Her2 cells and 10AT-Neo cells were initially
cultured in adherent monolayers and treated with or with-
out 200 μM I3C over 72 hours. The total cell number was
determined using the cell-counting kit-8 assay [53]. I3C
rapidly prevented the proliferation of 10AT-Her2 cells
Figure 3 Tumor xenograft-forming efficiency and tumorsphere and in vivo growth inhibition by I3C. (A) 10AT-Her2 cells were plated at a
density of 4,000 cells per well in tumorsphere culture conditions and incubated with or without 200 μM I3C. After 6 days in cell suspension
cultures, tumorsphere formation was assessed visually by phase microscopy and quantified. Scale bar represents 50 μm. (B) 10AT-Her2 cells
were plated at a density of either 4,000 cells per well or 25,000 cells per well in tumorsphere culture conditions and then incubated with 10 μM
1-benzyl-I3C (1BI), 200 μM I3C, 50 μM DIM, 200 μM tryptophol (Trp), 300 μM artemisinin (Art) or with the DMSO vehicle control (VC). After 6 days
in cell suspension cultures, tumorsphere formation was assessed visually by phase microscopy and quantified. (C) Three million 10AT-Neo cells
(Neo) or 300,000 10AT-Her2 cells (Her2) were implanted in athymic mice, and 20 separate tumor injection sites were examined for palpable
tumors after 5 weeks and quantified. (D) After the formation of detectable 10AT-Her2 cell-derived palpable tumor xenografts, athymic mice were
treated subcutaneously with either 300 mg/kg of I3C or the DMSO vehicle control. Tumor volumes were quantified with a caliper from ten
tumor xenografts per condition using two tumor sites per animal. The micrograph insert shows representative tumors excised from 2-week-post
injection animals. 1BI, 1-benzyl-I3C; Art, artemisinin; DIM, 3,3'-dimethylindolylmethane; Her2, 10AT-Her2; I3C, indole-3-carbinol; Neo, 10AT-Neo;
Trp, tryptophol; VC, vehicle control.
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right panel), whereas, proliferation of the control 10AT-
Neo cells remained relatively unaffected by I3C treatment
(Figure 4A, left panel). Flow cytometry of nuclear DNA
stained with propidium iodide revealed that 48 hours ofI3C treatment induced a significant increase in 10AT-
Her2 cells with a sub-G1 DNA content compared to
vehicle-control-treated cells, which is indicative of the ac-
tivation of apoptosis (Figure 4B, right panels). The control
10AT-Neo cells remained relatively resistant to I3C and
Figure 4 I3C induces p53-dependent apoptosis and regulation of MDM2–p53 and MDM2–nucleostemin protein–protein interactions.
(A) 10AT-Her2 and 10AT-Neo cells were treated with or without 200 μM I3C for the indicated durations and cell number was quantified by the
cell proliferation assay described in the Methods section. (B) 10AT-Neo and 10AT-Her2 cells were treated with or without 200 μM I3C for 48 hours.
The DNA content of nuclear DNA stained with propidium iodide was assessed by flow cytometry. (C) 10AT-Her2 cells were treated with or
without 200 μM I3C for 48 hours, total cell extracts were electrophoretically fractionated and then Western blots probed for PARP, Akt1, p53 and
the actin gel loading control. (D) 10AT-Her2 cells were transfected with either a dominant negative p53 (DN p53) expression vector or with
the empty expression vector (EV), and then treated with or without 200 μM I3C for 48 hours. The DNA content of nuclear DNA stained with
propidium iodide was assessed by flow cytometry. (E, F) 10AT-Her2 cells were treated with or without 200 μM I3C for 48 hours. Total cell extracts
were immunoprecipitated with either MDM2 (E) or nucleostemin (F) antibodies. As a control, non-immune antibodies (of immunoglobulin G or
IgG) and samples not immunoprecipitated (No IP) were used. All extracts were electrophoretically fractionated and probed by Western blot
analysis using antibodies specific to p53, serine-166 phosphorylated MDM2 or total MDM2 (E) or with antibodies specific to either serine-166
phosphorylated MDM2 or total MDM2 (F). DN, dominant negative; EV, empty expression vector; I3C, indole-3-carbinol; IgG, immunoglobulin G;
IP, immunoprecipitated; MDM2, murine double mutant 2; PARP, poly ADP ribose polymerase.
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G1-DNA content (Figure 4B, left panels). Under these
conditions, I3C treatment of 10AT-Her2 cells did not alter
the expression of the cancer stem/progenitor cell-like
marker proteins nucleostemin, CD44, CD24 and ALDH-1
(Figure 1A).To determine whether I3C induced an apoptotic re-
sponse and verify the sub-G1 DNA content observed by
flow cytometry, 10AT-Her2 cells were treated with or
without I3C. Western blots probed for the production of
cleaved poly ADP ribose polymerase (PARP) protein, a
substrate of activated caspase 3 in the apoptotic pathway
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stimulated PARP cleavage as shown by the detection of
significant levels of the 85-kDa PARP cleavage product,
and 10AT-Her2 cells express similar levels of the p53
tumor suppressor protein in the presence or absence of
I3C. It is well established that regulation of the p53
tumor suppressor protein plays an important role in the
control of cellular apoptosis [55]. Therefore, the poten-
tial role of p53 in the I3C apoptotic response was func-
tionally evaluated by transfection of 10AT-Her2 cells
with either a dominant negative (DN) p53 or an empty
expression vector (EV) as a control. Flow cytometry
of nuclear DNA stained with propidium iodide from
48-hour I3C-treated or untreated cells revealed that ex-
pression of DN p53 prevented the I3C-stimulated pro-
duction of sub-G1 DNA content, which is indicative of
loss of apoptosis, whereas I3C efficiently induced an
apoptotic response in 10AT-Her2 cells transfected with
the empty vector (Figure 4D).
One known mechanism by which the p53-dependent
apoptotic response can be regulated is through the dir-
ect binding of MDM2 to p53, which prevents the apop-
totic activity of p53 by sequestering p53 away from its
apoptotic targets [56]. MDM2 co-immunoprecipitations
were carried out to determine whether I3C treatment dis-
rupts the ability of MDM2 to interact with p53. 10AT-
Her2 cells were treated with or without I3C for 48 hours
and the immunoabsorbed MDM2 protein complex was
electrophoretically fractionated and Western blots probed
for the presence of p53 in the immunoabsorbed protein.
In the absence of I3C, a significant amount of p53 pro-
tein co-immunoprecipitated with MDM2, which shows
the presence of the MDM2–p53 protein interaction in
proliferating cells, whereas, in contrast, after I3C treat-
ment, the MDM2–p53 protein interaction is nearly ab-
lated (Figure 4E). This result suggests that the I3C
disruption of MDM2 binding to p53 frees this tumor
suppressor protein to trigger its apoptotic response. Con-
sistent with this concept, expression of a constitutively ac-
tive form of Akt-1, which phosphorylates MDM2 and
promotes MDM2 binding to p53 [56], prevented the I3C
apoptotic response and restored MDM2–p53 protein in-
teractions (data not shown).
Because I3C triggers anti-proliferative signaling in 10AT-
Her2 cells through a p53- dependent response, we exam-
ined whether cellular components that define the cancer
stem/progenitor cell-like phenotype may be associated
with the I3C regulation of the MDM2–p53 pathway. One
such intriguing molecular marker that is highly expressed
in self-renewing cancer stem/progenitor cells and is associ-
ated with the MDM2–p53 pathway is nucleostemin
[57-59], which is a nuclear GTPase that has been shown to
interact directly with MDM2 [57,60,61]. There is only lim-
ited information concerning the regulation or functionalsignificance of nucleostemin–MDM2 protein interactions
in human cancer cells [60,61]. I3C had no effect on the
total levels of nucleostemin protein (see Figure 1A) or total
MDM2 (Figure 4F, left panel) expressed in 10AT-Her2
cells, although the level of detectable serine-166 (Ser166)
phosphorylated MDM2 decreased in I3C-treated cells
(Figure 4F, left panel). Co-immunoprecipitations were
carried out by immunoadsorbing nucleostemin from
48-hour I3C-treated or untreated cells and then Western
blots probed for either the Ser166 phosphorylated
MDM2 or total MDM2 protein. As shown in Figure 4F,
I3C treatment strongly enhanced nucleostemin interac-
tions with both the Ser166 phosphorylated MDM2 protein
and the total MDM2 protein. This result suggests that the
I3C-induced interaction of nucleostemin with the Ser166
phosphorylated form of MDM2 prevents p53 from bind-
ing to MDM2 and accounts for the ability of this natural
indole carbinol compound to trigger a p53-dependent
apoptotic response in 10AT-Her2 cells.
To assess whether the I3C regulation of MDM2 pro-
tein interactions with p53 and/or nucleostemin occurs
in other indole-carbinol-sensitive breast cancer cells,
three well-established cell lines, SKBR3, MCF-7 and
MDA-MB-231, were treated with or without I3C for
48 hours and MDM2–p53 and nucleostemin–MDM2
co-immunoprecipitations carried out as described above
for 10AT-Her2 cells. As shown in Figure 5A, I3C dis-
rupted MDM2–p53 interactions and stimulated nucleos-
temin–MDM2 interactions in SKBR3 cells, a cell line that
expresses nucleostemin and other stem/progenitor cell-
like marker proteins approximately to the same levels as
the 10AT-Her2 cell population (Figure 2C). Therefore, the
effects of I3C on nucleostemin–MDM2 and MDM2–p53
interactions that we observed with 10AT-Her2 cells is not
limited only to this newly developed breast cancer cell
line. In contrast, even though MCF-7 and MDA-MB-231
cells are sensitive to the anti-proliferative effects of I3C,
there were no detectable changes in MDM2–p52 or
nucleostemin–p53 protein interactions after I3C treat-
ment (Figure 5B,C). Based on expression of marker pro-
teins, the relative stemness character of the MCF-7 and
MDA-MB-231 cell populations can be considered less
than that of either SKBR3 or 10AT-Her2 cells, which
may be associated with the lack of any effects of I3C treat-
ment on nucleostemin protein–protein interactions.
Interfering RNA knockdown of nucleostemin in 10AT-Her2
cells disrupts the I3C-stimulated localization of MDM2
into the nucleolus compartment, strongly attenuates the
I3C-induced apoptotic response and partially reverses the
loss of MDM2–p53 interactions
Given that nucleostemin resides in the nucleolus [57]
and MDM2 translocates between the cytoplasm and nu-
cleus [56], an intriguing issue is whether the I3C-induced
Figure 5 I3C regulation of nucleostemin–MDM2 and p53-MDM2 protein interactions in well-established human breast cancer cell lines.
SKBR3 (A), MCF-7 (B) and MDA-MB-231 (C) human breast cancer cells were treated with or without 200 μM I3C for 48 hours. Total cell extracts
were immunoprecipitated with either MDM2 (top panels for each cell line) or nucleostemin (lower panels for each line) antibodies. As a control,
non-immune antibodies (IgG) and samples not immunoprecipitated (No IP) were used. All extracts were electrophoretically fractionated and
probed by Western blot analysis using antibodies specific to p53 (top panels) or with antibodies specific to serine-166 phosphorylated MDM2
or total MDM2 (lower panels). The levels of actin protein remaining in the cell extracts after the immunoprecipitations were used as gel-loading
controls in each experiment. I3C, indole-3-carbinol; IgG, immunoglobulin G; IP, immunoprecipitated; MDM2, murine double mutant 2;
NS, nucleostemin.
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of MDM2 to the nucleus in I3C-treated cells. This possi-
bility was functionally examined by siRNA knockdown of
nucleostemin. Western blots showed that nucleostemin
siRNA efficiently reduced the levels of nucleostemin com-
pared to cells receiving scrambled siRNA (Figure 6A). The
localization of MDM2 was initially examined in cells
treated for 48 hours with or without I3C and then bio-
chemically fractionated into nuclear and cytoplasmic
extracts. Western blots showed that in cells transfected
with scrambled siRNA, I3C treatment causes the redistri-
bution of MDM2 from cytoplasmic and nuclear fractions
into predominantly the nuclear fraction (Figure 6B). Incontrast, knockdown of nucleostemin prevented the I3C-
induced subcellular localization of MDM2 into the nu-
clear fraction. Under each condition, the cytoplasmic
fraction remained enriched in the cytoplasmic marker
HSP90, whereas the nuclear compartment was enriched
in nuclear marker lamin.
In 10AT-Her2 cells transfected with scrambled siRNA,
indirect immunofluorescence revealed that nucleostemin
is localized to punctate foci in the nucleus in the presence
or absence of I3C, which is indicative of the nucleolus
compartment (Figure 6C, left set of panels). Strikingly,
I3C treatment triggered the redistribution of MDM2 from
both the nucleus and cytoplasm, to an enriched punctate
Figure 6 Nucleostemin-dependent I3C stimulation of MDM2 nuclear compartmentalization and localization into nucleolus foci.
10AT-Her2 cells were transfected with either control scramble siRNA or nucleostemin siRNA, and then treated with or without 200 μM I3C for
48 hours. (A) The level of nucleostemin protein was determined by Western blot analysis. (B) Cell extracts were biochemically separated into
nuclear enriched and cytoplasmic fractions, electrophoretically fractionated, and Western blots probed with antibodies specific for MDM2, the
cytoplasmic marker HSP90 and the nuclear marker lamin. (C) The subcellular localization of MDM2 and nucleostemin was determined by indirect
immunofluorescence microscopy. DAPI staining was used to visualize DNA stained nuclei. Scale bar represents 4 μm. DAPI, 4',6-diamidino-2-
phenylindole; DMSO, dimethyl sulfoxide; I3C, indole-3-carbinol; MDM2, murine double mutant 2; NS, nucleostemin; siRNA, small interfering RNA.
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of panels, see arrows). Merging of the nucleostemin and
MDM2 immunofluorescence staining in the scrambled
siRNA transfected cells treated with I3C revealed that
nucleostemin and MDM2 co-localize into identical foci
staining patterns (Figure 6, merged staining panel). Im-
portantly, siRNA knockdown of nucleostemin completely
disrupted the nuclear foci staining of MDM2 in I3C-
treated cells, and the overall localization of MDM2 resem-
bled that observed in cells not treated with I3C (Figure 6C,
right set of panels).
To determine whether the I3C apoptotic response in
10AT-Her2 cells requires expression of nucleostemin, cells
transfected with either nucleostemin or scrambled siRNA
were treated with or without I3C for 48 hours. The relative
apoptotic response was quantified as the ratio of sub-G1content DNA in untreated to I3C-treated cells. As shown
in Figure 7A, siRNA knockdown of nucleostemin signifi-
cantly attenuated the apoptotic response compared to that
observed in 10AT-Her2 cells transfected with scrambled
siRNA. Co-immunoprecipitations of I3C-treated and un-
treated cells demonstrated that knockdown of nucleoste-
min partially reversed the I3C disruption of MDM2–p53
protein interactions (Figure 7B). The level of MDM2–p53
interactions in I3C-treated cells transfected with nucleoste-
min siRNA was approximately the same as vehicle-control-
treated scramble siRNA transfected cells (Figure 7B).
Interestingly, siRNA knockdown of nucleostemin in-
creased the overall levels of p53. Also, I3C treatment
efficiently inhibited production of Ser166 phosphory-
lated MDM2 regardless of the presence of nucleostemin
(Figure 7C), suggesting that this regulated step is upstream
Figure 7 Effects of nucleostemin knockdown on I3C-induced apoptotic response and regulated MDM2- p53 protein interactions. (A)
10AT-Her2 cells transfected with nucleostemin siRNA or with scrambled siRNA control were treated with or without 200 μM I3C for the indicated
durations. The relative amount of apoptosis was quantified by the ratio of sub-G1 DNA content as determined by flow cytometry. The number of
apoptotic cells observed after I3C treatment was normalized to the number of apoptotic cells observed in DMSO-vehicle-control-treated cells.
(B) 10AT-Her2 cells were transfected with either scrambled siRNA or nucleostemin-specific siRNA, and then treated with or without 200 μM I3C
for 48 hours. Total cell extracts were immunoprecipitated with MDM2 antibodies, electrophoretically fractionated and Western blots probed with
p53-specific antibodies. Negative control immunoprecipitations were carried out with non-immune antibodies (IgG) or samples that were not
immunoprecipitated (No IP). (C) Western blots of total cell extracts (total protein) were analyzed for p53, serine-166 phosphorylated MDM2 and
total MDM2. DMSO, dimethyl sulfoxide; I3C, indole-3-carbinol; IgG, immunoglobulin G; IP, immunoprecipitated; MDM2, murine double mutant 2;
NS, nucleostemin; siRNA, small interfering RNA.
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Taken together, these results demonstrate that I3C re-
quires the nucleostemin cancer stem cell marker to
trigger its apoptotic anti-proliferative pathway in the
10AT-Her2 cell population.
Expression of an I3C-resistant form of elastase in 10AT-Her2
cells disrupts the indole carbinol apoptotic response, and
reverses the I3C effects on MDM2–p53, nucleostemin–MDM2
and CD40–TRAF6 protein–protein interactions
We previously established that elastase is the biologically
relevant indole carbinol target protein in human breastcancer cells, and the non-competitive inhibition of elas-
tase enzymatic activity by I3C triggers a shift from cell
survival signaling to apoptotic signaling that is mediated
by altered signaling through downstream elastase sub-
strates such as the CD40 member of the tumor necrosis
factor receptor gene family [33,34,48]. The indole carbi-
nol inhibition of elastase activity prevents the processing
and cleavage of CD40 that results in the stable production
of the full-length 44-kDa form of CD40 [34]. Because elas-
tase is the only established direct target protein for I3C,
we assessed whether elastase is required for the I3C anti-
proliferative signaling in the 10AT-Her2 cell population.
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with expression vectors encoding the wild-type (WT) elas-
tase or the Δ205 I3C-resistant form of elastase, which has
a carboxyterminal truncation and remains highly enzy-
matically active but resistant to the inhibitory effects of
I3C [48]. Another set of 10AT-Her2 cells was transfected
with the EV. Transfected 10AT-Her2 cells were treatedFigure 8 Elastase-dependent I3C apoptotic effects, regulation of prot
xenografts. (A) 10AT-Her2 cells were transfected with either the EV, WT el
vector and treated with or without 200 μM I3C for 48 hours. Cell extracts w
analysis for CD40, Akt1 and HSP90. (B) 10AT-Her2 cells were transfected wi
200 μM I3C for 48 hours. The relative amount of apoptosis was quantified
of nuclear DNA stained with propidium iodide. The number of apoptotic cells
treated cells. (C, D, E) 10AT-Her2 cells were transfected with EV, WT or Δ205 e
Total cell extracts were immunoprecipitated with either CD40 (C) nucleostem
carried out with non-immune antibodies (IgG) or not immunoprecipitated (N
Western blot analysis using antibodies specific to tumor necrosis factor recep
(F) 10AT-Her2 cells were stably transfected with EV, WT or Δ205 expression ve
mice. After the formation of detectable palpable tumor xenografts, athymic m
DMSO vehicle control. Tumor volumes were quantified with a caliper from te
micrograph insert shows representative tumors excised from 2-week-post-inje
I3C, indole-3-carbinol; IgG, immunoglobulin G; IP, immunoprecipitated; MDM2
activator factor-6; WT, wild type.with or without I3C for 48 hours. Western blots of total
cell extracts demonstrated that in cells transfected with
the WT elastase or the EV, the level of the uncleaved
44-kDa form of CD40 is significantly enhanced after I3C
treatment (Figure 8A), which is indicative of an inhibition
of elastase activity [34]. In 10AT-Her2 cells expressing the
I3C-resistant elastase (Δ205), the level of uncleaved CD40ein–protein interactions, and inhibition of in vivo tumor
astase expression vector or the Δ205 truncated elastase expression
ere electrophoretically fractionated and probed by Western blot
th EV, WT or Δ205 expression vectors and treated with or without
by the ratio of sub-G1 DNA contents as determined by flow cytometry
observed after I3C treatment were normalized to DMSO-vehicle-control-
xpression vectors and treated with or without 200 μM I3C for 48 hours.
in (D) or MDM2 (E) antibodies. As controls, immunoprecipitations were
o IP). Cell extracts were electrophoretically fractionated and probed by
tor activator factor-6 (TRAF6) (panel C), MDM2 (panel D) or p53 (panel E).
ctors and 300,000 cells were used for xenograft injections of athymic
ice were treated subcutaneously with either 300 mg/kg of I3C or the
n tumor xenografts per condition using two tumor sites per animal. The
ction animals. DMSO, dimethyl sulfoxide; EV, empty expression vector;
, murine double mutant 2; TRAF6, tumor necrosis factor receptor
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treated cells (Figure 8A), which confirms that this trun-
cated elastase remains active under both conditions.
Co-immunoprecipitations revealed that in 10AT-Her2
cells transfected with either the WT elastase or the EV,
I3C treatment disrupted the binding of CD40 with one
of its immediate downstream effectors, tumor necrosis
factor receptor activator factor-6 (TRAF6), which is an
E3 ubiquitin ligase that can ubiquitinate Akt-1 [62]. In
contrast, in cells expressing the Δ205 I3C-resistant elastase,
TRAF6 remained associated with CD40 in the presence or
absence of I3C treatment (Figure 8C, right panels). The
total levels of TRAF6 remained unaffected by I3C treat-
ment (Figure 8C, left panels). Consistent with the I3C-
regulated release of TRAF6 from CD40 in cells expressing
endogenous (EV) or exogenous (WT) elastase, the protein
levels of Akt-1 decreased in I3C-treated cells, whereas, in
cells expressing the I3C-resistant elastase (Δ205), the levels
of Akt-1 protein remained unaltered after I3C treatment
(Figure 8A, middle panel).
To determine the dependence of elastase in the I3C
apoptotic response, 10AT-Her2 cells transfected with the
WT elastase gene, the I3C-resistant form of elastase or
the EV were treated with or without I3C for 48 hours. Nu-
clear DNA stained with propidium iodide was analyzed by
flow cytometry. The apoptotic response was quantified by
the ratio of sub-G1 DNA content in I3C-treated to un-
treated cells. As shown in Figure 8B, 10AT-Her2 cells ex-
pressing the I3C-resistant elastase were mostly resistant to
the indole-carbinol-induced apoptosis, whereas cells ex-
pressing either endogenous (EV) or exogenous (WT) elas-
tase remained highly sensitive to the anti-proliferative
effect of I3C. This result establishes a role for the I3C
target protein elastase in mediating the anti-proliferative
effects of this natural indole carbinol compound. Co-
immunoprecipitation analysis demonstrated that com-
pared to 10AT-Her2 cells expressing endogenous or
exogenous WT elastase, expression of the Δ205 I3C-
resistant elastase reversed the I3C stimulation of nucleos-
temin–MDM2 interactions (Figure 8D) and prevented I3C
from disrupting MDM2–p53 interactions (Figure 8E).
These results directly establish a functional connection be-
tween the I3C-dependent regulation of signaling through
the I3C target protein elastase and the control of protein–
protein interactions directed by the cancer stem/progeni-
tor cell marker protein nucleostemin.
In vivo requirement for elastase in the I3C inhibition of
10AT-Her2 cell-derived tumor xenograft growth
The functional role of elastase in mediating the in vivo
effects of I3C on tumor xenograft growth was deter-
mined by implanting NIH III athymic mice with 300,000
10AT-Her2 cells stably transfected with either the WT
or I3C-resistant Δ205 forms of elastase as well as cellstransfected with the EV. Tumors were allowed to reach
an average volume of 200 mm3 before they began to re-
ceive subcutaneous injections of I3C or the DMSO vehicle
control. Tumor volumes were monitored throughout
21 days. Growth of the tumor xenografts formed with
10AT-Her2 cells transfected with the WT elastase was
strongly inhibited in animals injected with I3C compared
to animals injected with the vehicle control (Figure 8F,
WT I3C vs WT vehicle). Cells expressing the EV were
similarly sensitive to I3C (data not shown). In contrast,
the tumor xenografts formed from 10AT-Her2 cells stably
transfected with the I3C-resistant Δ205 elastase, were
completely resistant to I3C and the tumor volumes in
I3C-treated and vehicle-control-treated animals were vir-
tually identical (Figure 8F, Δ205 I3C vs Δ205 vehicle). The
micrographs in Figure 8 show representative tumor xe-
nografts after 21 days of growth in I3C-treated and
vehicle-control-treated animals. In the cells expressing
the endogenous or exogenous WT elastase, the tumor
xenografts from I3C-treated animals were smaller in
size and they appeared less vascularized and displayed
pliable texture suggestive of reduced density compared
to tumor xenografts from vehicle-control-treated ani-
mals. In contrast, the tumor xenografts formed from
10AT-Her2 cells expressing the I3C-resistant Δ205 elas-
tase displayed similar sizes and characteristics in the
presence or absence of I3C treatment. Therefore, the
I3C regulation of the in vivo growth of the 10AT-Her2 cell
population highly enriched in cells with cancer stem/pro-
genitor cell-like properties requires expression of the
indole-carbinol-sensitive elastase.
Discussion
Cancer stem/progenitor cell populations have been isolated
in clinical samples of breast cancer tissue that characteris-
tically show a CD44+/CD24–/lin− phenotype [63-67] and
also preferentially express other stem cell markers such as
nucleostemin and active ALDH-1 [64,68,69]. The ability to
evaluate the efficiency of anti-cancer agents in targeting
breast cancer stem cells has been limited by the low num-
ber of stem cells that can be isolated from tumors and by
the loss of viability and/or instability of the stem cell
phenotype once the cells are cultured outside the in vivo
context [63,70-72]. By expressing HER2 in human preneo-
plastic mammary epithelial cells, forming the 10AT-Her2
cell line, we generated a new human breast cancer cell sys-
tem in which the overall cell population is highly enriched
with cells that stably display breast cancer stem/progenitor
cell-like properties. The 10AT-Her2 cell population, but
not the EV-transfected 10AT-Neo preneoplastic cells, are
CD44+/CD24–/low/ALDH-1+ with high levels of nucleoste-
min. Analysis of cell surface expression of the CD44 cancer
stem/progenitor marker protein by flow cytometry showed
that approximately 98% of cells in the 10AT-Her2 cell
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almost 90% of the cell population contains active ALDH-1.
Consistent with the existence of an enriched population of
cells with tumor-initiating properties, 10AT-Her2 cells effi-
ciently form tumorspheres in suspension cell cultures and
in vivo form tumor xenografts with significantly lower
numbers of implanted cells compared to well-established
highly tumorigenic human breast cancer cell lines.
Based on the expression pattern of nucleostemin, CD44,
CD24 and ALDH-1, the stemness character of the SKBR3
human breast cancer population is similar to that of the
10AT-Her2 cell population, whereas MCF-7 and MDA-
MB-231 cells express significantly lower levels of nucleos-
temin and do not produce detectable levels of ALDH-1.
These protein expression patterns suggest that the 10AT-
Her2 breast cancer cell line does not display abhorrent
properties with regard to the production of stem/progeni-
tor cell marker proteins. Several cellular properties of
10AT-Her2 cells suggest that the cell population is more
enriched in stem/progenitor cell-like cells compared to
the three tested human breast cancer cell lines. For the
highly tumorigenic MCF-7 and SKBR3 cells, typically sev-
eral million cells are required to be implanted into athy-
mic mice in order to detect a high percentage of tumor
xenografts. Importantly, in contrast, a near 100% tumor
xenograft formation efficiency occurs when only 300,000
10AT-Her2 cells are implanted into athymic mice, and a
significant percentage of tumors per inject site can be de-
tected even when as few as 20,000 cells are implanted.
Also, the in vitro tumorsphere-forming efficiency of the
10AT-Her2 cells is at least 100-fold greater than SKBR3
cells, even though both cell lines express comparable
levels of stem/progenitor cell-like marker proteins.
The rationale for expressing exogenous HER2 into pre-
neoplastic mammary epithelial cells to form the 10AT-
Her2 cell line is the functional connection between elevated
HER2 levels and enhanced cancer stem/progenitor cell
populations that can be detected in primary breast tumors
and cancer cell lines [13]. Expression of exogenous HER2
in breast cancer cells enhanced the occurrence of side-
populations of tumor-initiating cells of the luminal subtype
profile [12,13,73,74]. Also, HER2 can be clinically correlated
with stem/progenitor cell populations in that patients with
HER2+ breast cancers treated with the HER2 inhibitor
lapatinib show a significant reduction in the number of
CD44+/CD24–/low cells and a decreased tumorsphere-
forming efficiency [12,75,76]. 10AT-Her2 cells and the
established SKBR3 breast cancer cell line express gener-
ally similar levels of Her2 protein; however, the 10AT-
Her2 cells form tumorspheres and tumor xenografts at
significantly lower cell numbers compared to SKBR3
cells. Thus, the level of HER2 protein per se is not the
singular determining factor for the generation of the
cancer stem/progenitor cell-like character of our newlydeveloped breast cancer model system. Conceivably a
combination of HER2 signaling and the components con-
stituting the preneoplastic phenotype caused the emer-
gence of cells enriched with cancer stem/progenitor
cell-like properties in the 10AT-Her2 cell population.
We observed that 10AT-Her2 cells are highly sensitive
to the anti-proliferative effects of I3C, a natural indole
carbinol compound. I3C was shown to trigger a p53-
dependent apoptotic response in 10AT-Her2 cells and
can disrupt tumorsphere formation in cell suspension
cultures as well as inhibit the in vivo growth of 10AT-
Her2-derived tumor xenografts. Because the 10AT-Her2
cell population expresses relatively high levels of nucleoste-
min, this system was used to determine whether this breast
cancer stem/progenitor marker protein can be potentially
targeted by and confer selective responsiveness to I3C.
Nucleostemin is a multidomain nucleolus GTPase, which
is associated with self-renewal of undifferentiated stem/
progenitor cells [60,61]. Co-immunoprecipitations revealed
that I3C treatment of 10AT-Her2 cells strongly promoted
nucleostemin binding to the MDM2 inhibitor of the p53
tumor suppressor, and thereby sequestered MDM2 into
the nucleolus. Although I3C decreased the amount of
p-MDM2, this natural indole carbinol compound appears
to increase significantly the binding efficiency between
phosphorylated MDM2 and nucleostemin. An important
consequence of the induced nucleostemin–MDM2 inter-
action is that I3C treatment prevented MDM2 binding to
p53, which we propose allows the p53 tumor suppressor
protein to escape the MDM2 inhibition and initiate its
cellular apoptotic response (see Figure 9). We also ob-
served the I3C-regulated nucleostemin–MDM2 as well
as MDM2–p53 interactions occur in SKBR3 breast can-
cer cells, but not in either MCF-7 or MDA-MB-231
cells even though all three of these human breast cancer
cell lines are sensitive to the anti-proliferative effects of
I3C. Conceivably, the attenuated stemness properties of
MCF-7 and MDA-MB-231 cells may account for this
difference in I3C-regulated protein–protein interaction
properties. Consistent with this pathway mediating the
anti-proliferative effects of I3C, expression of dominant
negative p53 prevented the I3C apoptotic response in
10AT-Her2 cells, whereas knockdown of nucleostemin
disrupted the I3C-induced localization of MDM2 into
nuclear foci as well as strongly attenuated the apoptotic
response. I3C did not alter the protein level of nucleoste-
min, MDM2 or p53, implying that the key effects are on
protein–protein interactions and subcellular localization
(see Figure 9).
Knockdown studies of nucleostemin have been contro-
versial as to whether nucleostemin has a cancer promot-
ing or an anti-cancer effect. It appears that the cellular
role of nucleostemin is likely to vary in a cell-type-specific
manner. Consistent with our observations, the aberrant
Figure 9 Proposed model of the elastase-dependent I3C anti-proliferative cascade that targets and requires nucleostemin. (A) In
proliferative cells in the absence of I3C, the elastase cleavage of CD40 triggers signaling through TRAF6 that results in activated Akt phosphorylation of
MDM2. As a result, MDM2 interacts with both the nuclear and cytoplasmic forms of p53 and thereby prevents the apoptotic activity of this tumor
suppressor protein. Under these proliferative conditions, nucleostemin remains in a nucleolus compartment. (B) I3C inhibits the elastase cleavage of
CD40 and thereby disrupts the CD40–TRAF6 interaction and inhibits signaling through TRAF6, which results in the loss of MDM2 phosphorylation. The
non-phosphorylated MDM2 and phosphorylated MDM2 are sequestered into the nucleolus by their interaction with nucleostemin, which then releases
p53 to mediate its apoptotic response. The I3C anti-proliferative cascade is disrupted by expression of an I3C-resistant form of elastase, by the siRNA
knockdown of nucleostemin, or by the expression of a dominant negative p53. I3C, indole-3-carbinol; MDM2, murine double mutant 2; NS,
nucleostemin; TRAF6, tumor necrosis factor receptor activator factor-6.
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cycle arrest via inhibition of MDM2 [60], whereas, deple-
tion of nucleostemin destabilized MDM2 and induced a
p53-dependent cell cycle arrest [61]. Relatively little is
known about the functional significance of nucleostemin–
MDM2 interactions [57,60,61]. Our observations provide
the first direct evidence that anti-proliferative signaling
by I3C can promote specific interactions of the breast
cancer stem/progenitor cell marker protein nucleoste-
min with the MDM2 inhibitor of p53. It is interesting to
note that the presence of nucleostemin per se is not suf-
ficient to sequester MDM2 into nucleolus foci becausethe sequestration of MDM2 is only observed after I3C
treatment, even though nucleolus-localized nucleoste-
min was detected in 10AT-Her2 cells regardless of I3C
treatment. We did not observe changes in the total level
of p53 protein in several experimental contexts, and our
results suggest that the loss of MDM2 accessibility to p53
frees p53 to trigger its apoptotic response. The MDM2
interaction with p53 was partially reversed in I3C-treated
cells after knockdown of nucleostemin, suggesting that in
the absence of nucleostemin, MDM2 can still interact
with p53, although at lower efficiency. It is tempting to
speculate that I3C-induced signaling pathways may
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ism that enhances the nucleostemin–MDM2 protein–pro-
tein interaction. Consistent with this possibility, I3C
treatment significantly reduced the level of phosphorylated
MDM2, which in other systems can influence MDM2–p53
interactions [56]. Phosphorylation of MDM2 at Ser166 by
Akt1 is critical in maintaining the MDM2–p53 interaction
[77,78]. Our preliminary evidence shows that transfection
with constitutively active Akt1 reversed the loss of MDM2
phosphorylation in the presence of I3C, prevented the ob-
served apoptotic response and attenuated the I3C-induced
interaction of MDM2 with nucleostemin.
We previously established that elastase is the biologic-
ally relevant indole carbinol target protein in breast can-
cer cells and the noncompetitive inhibition of elastase
enzymatic activity by I3C, and other I3C-based derivatives,
triggers a shift from cell survival signaling to apoptotic sig-
naling by altering the signaling through downstream elas-
tase substrates, such as the CD40 member of the tumor
necrosis factor receptor gene family [34,48]. The elastase
cleaved form of CD40 directly interacts with a specific set
of downstream effectors (tumor necrosis factor receptor
activator factors or TRAFs) to activate cell survival signal-
ing cascades, whereas the uncleaved form of CD40 inter-
acts with a different set of TRAFs to initiate an apoptotic
response [34,79,80]. The requirement for elastase in I3C
apoptotic signaling in 10AT-Her2 cells was established by
expressing the WT elastase or a novel I3C-resistant trun-
cated form of elastase, which remains highly enzymatically
active but resistant to the inhibitory effects of I3C [48].
Co-immunoprecipitations showed that in the presence of
the WT elastase, I3C treatment released the CD40 bind-
ing with TRAF6, which is an E3 ubiquitin ligase respon-
sible for the recruitment of active Akt1 to the plasma
membrane [59]. In the presence of the I3C-resistant elas-
tase, CD40 is cleaved in the presence or absence of I3C
and TRAF6 remained associated with CD40 under both
conditions. Also, in cells expressing the I3C-resistant
elastase, treatment with I3C failed to stimulate the
MDM2–nucleostemin or inhibit the MDM2–p53 bi-
molecular interactions, and prevented I3C from trigger-
ing its apoptotic response in cell cultures or to inhibit
growth of 10AT-Her2 cell-derived tumor xenografts.
Therefore, we propose that in 10AT-Her2 cells, which
are highly enriched with cells with stem/progenitor cell-
like properties, the I3C apoptotic response is triggered
by the inhibition elastase and requires the downstream
protein–protein interactions of nucleostemin, a stem/
progenitor cell marker protein (see Figure 9 diagram).
Conclusions
An intriguing potential clinical significance of our
mechanistic studies is the potential development of
I3C-based compounds in new therapeutic strategies thatblock the emergence and maintenance of stem/progeni-
tor cell populations within breast cancers by inducing a
nucleostemin-dependent apoptotic response. Our pre-
clinical characterization of the mechanism of action of
I3C has shown that the nucleostemin stem/progenitor
cell marker protein is essential for the anti-proliferative
response of this indole carbinol compound. Given that
I3C anti-proliferative signaling requires the presence of
WT elastase, which is the only identified direct target
protein for I3C, conceivably cancer stem/progenitor cell
populations in breast cancers that express both elastase
and nucleostemin should be highly sensitive to this indole
carbinol compound. In this regard, many advanced-stage
breast cancers express high levels of elastase or elastase
activity [81,82], and it is tempting to consider that the de-
tection of elastase activity in biopsies could eventually lead
to the use of I3C-based compounds for individual pa-
tients. Prior to the development of personalized therapies,
a critical issue will be to determine whether the cancer
stem/progenitor cells that exist in early and/or advanced
breast tumors produce high enough levels of elastase
and nucleostemin to be sensitive to I3C and its highly
potent derivatives. The 10AT-Her2 cell line, which has a
stable phenotype and is highly enriched with cells that
display breast cancer stem/progenitor cell-like proper-
ties, will be used to characterize the precise functional
role of signal-regulated alterations in nucleostemin–pro-
tein interactions that are part of the anti-proliferative
response to I3C, and can be employed to assess the effi-
ciency by which other classes of anti-cancer agents can
target specific stem/progenitor cell components in cancer
cell populations.
Advanced-stage breast cancers are notoriously difficult
to treat but generally possess high levels of WT elastase,
the direct target protein that triggers I3C anti-proliferative
signaling. Therefore, the broader community-focused sig-
nificance of our pre-clinical work is the potential to de-
velop low-cost I3C-based compounds as potential cancer
stem/progenitor cell-targeted treatment options for
women impacted by highly aggressive and metastatic
breast cancers.
Methods
Expression plasmids and transfections
Human cytomegalovirus CMV-HER2 and CMV-Akt1
expression plasmids were kind gifts from Dr Leonard
Bjeldanes (Department of Nutritional Sciences and Toxi-
cology, University of California at Berkeley). The CMV-
p53 dominant negative expression vector was a kind gift
from Dr Lin He (Department of Molecular and Cell Biol-
ogy, University of California Berkeley). The WT elastase
and I3C-resistant Δ205 elastase expression vectors were as
previously described [46]. Transfection of expression vec-
tors was performed using Superfect transfection reagent
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facturer’s recommended protocol.
Generation of the 10AT-Her2 and 10AT-Neo cell lines and
cell culture methods
Preneoplastic MCF-10AT human mammary epithelial
cells (obtained from the Barbara Ann Karmanos Cancer
Institute, Detroit, MI, USA) were stably transfected with
either the human pCMV-HER2 expression vector or
with the pCMV-Neo control vector forming 10AT-Her2
cells and 10AT-Neo cells, respectively. Cells were stably
selected for 2 months with G418 sulfate, purchased from
Cellgro (Manassas, VA, USA). 10AT-Her2 and 10AT-Neo
cell lines were cultured in DMEM/F-12, 10% fetal bovine
serum, 50 U/ml penicillin/streptomycin (Lonza, Allendale,
NJ, USA), 0.02 μg/ml epidermal growth factor (Promega,
Madison, WI, USA), 0.05 μ g/ml hydrocortisone, 10 μg/ml
insulin and 0.1 μg/ml cholera toxin (Sigma-Aldrich, St
Louis, MO, USA). MCF-7 breast cancer cells were cul-
tured in DMEM, 10% fetal bovine serum, 50 U/ml penicil-
lin/streptomycin, 2 mmol/l L-glutamine (Sigma-Aldrich,
St Louis, MO, USA), and 10 mg/ml insulin (Sigma-
Aldrich, St Louis, MO, USA). SKBR3 breast cancer
cells were cultured similarly but without the supplementa-
tion of insulin. Cells were grown to subconfluency in a
humidified chamber at 37°C containing 5% CO2. I3C,
DMSO and MG132 were obtained from Sigma-Aldrich.
For drug treatments, a 200 mmol/l stock solution of I3C
was purchased from Sigma-Aldrich, dissolved in DMSO
and then diluted in the ratio 1:1,000 in media before cul-
ture plate application. Before each drug treatment, cells
were washed in ice-cold PBS, which was obtained from
Lonza (Basel, Switzerland).
The 10AT-Her2 cell line, the parental MCF-10AT cells
and the SKBR3 breast cancer cell line were validated by
short tandem repeat (STR) DNA fingerprinting using
DDC Medical Cell Line Authentication Lab Services
(Fairfield, OH, USA). The STR profiles were compared
to known ATCC fingerprints [83] and to the Cell Line
Integrated Molecular Authentication database (CLIMA)
version 0.1.200808 [84]. The STR profile of the 10AT-
Her2 cell line matched that of its parental MCF-10AT
cell line, whereas the SKBR3 cells matched the known
DNA fingerprints to that of itself. Therefore, the cell
population of the 10AT-Her2 cell line, which displays
significant stemness-like character, is not contaminated
with any other cell line, such as SKBR3 cells that also
display some stemness-like character in the correspond-
ing cell population.
Tumorsphere formation
Single-cell suspensions of the indicated cell lines were
plated on ultra-low attachment plates (purchased from
Corning Costar, Corning, NY, USA) in MammoCultHuman Medium (Stem Cell Technologies, Vancouver,
Canada) and cultured at 37°C, 5% CO2. Cells were incu-
bated with or without 200 μM I3C for the indicated times
and tumorsphere formation was assessed and quantified
visually by phase microscopy.
Cell proliferation assay
The sensitivity of cells to I3C was examined using the
Cell-Counting Kit-8 (Dojindo Molecular Technologies,
Inc, Santa Clara, CA, USA) based on the manufacturer’s
recommended protocol [53]. Cells were plated at a dens-
ity of 5,000 to 7,000 cells per well in 24-well plates con-
taining 500 μl of culture medium. After the indicated
treatment and incubation times at 37°C, 40 μl CCK-8 re-
agent was then added to each well, which were then in-
cubated for 2 hours before reading at a wavelength of
450 nm.
Flow cytometry and ALDEFLUOR assay
The flow cytometry analysis was performed as previously
described [49]. To analyze cell surface expression of CD44
and CD24, harvested cells were incubated for 1 hour at 4°C
with CD44- or CD24-specific antibodies conjugated to
Alexafluor488 secondary antibodies. Cells were suspended
in full media and kept on ice pending analysis. The
ALDEFLUOR assay of ALDH-1 activity was performed
based on the manufacturer’s protocol (Stem Cell Tech-
nologies, Vancouver, BC, Canada). Live single cells were
gated for analysis using a Beckman-Coulter EPICS XL-
MCL flow cytometer (Beckman Coulter, Brea, CA, USA)
with a single 488-nm blue laser filtered at 525 BP/slot 1.
Western blots
After the indicated treatments, Western blots were per-
formed as previously described [51]. Briefly, cells were
harvested in ice-cold PBS and lysed using a radioimmu-
noprecipitation assay buffer (150 mM NaCl, 0.5% deoxy-
cholate, 0.1% NoNidet-p40, 0.1% SDS, 50 mM Tris)
containing protease and phosphatase inhibitors (50 g/ml
phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, 5 g/ml
leupeptin, 0.1 g/ml NaF, 1 mM dithiothreitol, 0.1 mM
sodium orthovanadate and 0.1 mM β-glycerol phosphate).
After centrifugation, total protein in the lysate was
estimated using the protein quantification kit (Bio-Rad,
Hercules, CA, USA). Cell lysates were electrophoretically
fractionated using SDS-PAGE and transferred to nitrocel-
lulose membranes. The blots were blocked with 5% nonfat
dry milk for an hour at room temperature and incubated
with primary antibodies overnight at 4°C. Immunoreactive
proteins were detected after a 1-hour incubation with
horseradish peroxidase conjugated secondary antibodies.
Blots were then treated with enhanced chemilumines-
cence reagents (Estman Kodak, Rochester, NY, USA) for
visualization on film. Primary antibodies, nucleostemin,
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(sc-22588), MDM2 (sc-5304), p53 (sc-6243), and lamin
(sc-7293), CD40 (sc-975), TRAF6 (sc-8409) Akt1 (sc-
5298) were purchased from Santa Cruz Biotechnology.
Actin (AANO1) was obtained from Cytoskeleton (Denver,
CO, USA). HER2 (2165), PARP (9542), and phospho-
MDM2 (3521 s) were obtained from Cell Signaling
Technology, Inc (Danvers, MA, USA). All antibodies
were diluted 1:1000 in TBST (0.1 M Tris, 150 mM
NaCl, 0.05% Tween 20).
Co-immunoprecipitation
After the indicated treatments, immunoprecipitations
were performed as described previously [85]. Pre-cleared
samples were then incubated with 50 μg of specific anti-
bodies as indicated overnight at 4°C. Immunoprecipitated
protein was eluted from beads by addition of gel-loading
buffer (50 mM Tris–HCl, pH 6.8, 2% SDS, 10% glycerol,
1% β-mercaptoethanol, 12.5 mM ethylenediaminetetraace-
tic acid (EDTA), 0.02 mM bromophenol blue) and heating
the sample at 100°C for 5 min. Samples were analyzed by
Western blot. The immunoprecipitation procedure was
nearly 100% efficient because the resulting supernates did
not contain any of the proteins of interest. If any of the
intended immunoprecipitated protein was detected in a
given supernatant fraction, that experiment was not used
for the study. Also, the “No IP” control in each experiment
represents samples that were subjected to the usual im-
munoprecipitation procedure except that the beads were
added without the antibody.
Transfection of small interfering RNA
Cells were grown and indicated treatments performed
on 10-cm tissue culture plates from Nalgene Nuc Inter-
national (Rochester, NY, USA). Once cells reached 50%
confluency, transfection with control or nucleostemin-
specific siRNA was performed using HiPerfect transfection
reagent based on the manufacturer's protocol (QIAGEN,
Germantown, MD, USA).
Nuclear and cytoplasmic fractionation
10AT-Her2 cells were grown and indicated treatments
were performed on 10-cm plates. Once harvested with ice-
cold PBS, nuclear extractions were performed using the
manufacturer’s guidelines (Thermo Scientific, Rockford, IL,
USA). Briefly, cells were vortexed for 15 seconds in cyto-
plasmic extraction reagent and placed on ice for 1 min.
This was repeated twice and then they were centrifuged at
16,000 g for 5 min at 4°C. The supernatant of the separated
cytoplasm was removed and the pellet was suspended in
nuclear extraction reagent and subsequently vortexed for
15 seconds and placed on ice for 10 min. This process was
repeated four times and the nuclear sample was thencentrifuged at 16,000 g for 5 min at 4°C. Samples were ana-
lyzed by Western blot analysis.
Indirect immunofluorescence
Indirect immunofluorescence was performed as previously
described [34]. Briefly, cells were grown and indicated
treatments performed on two-well chamber slides from
the Nalgene Nunc International subsidiary of Thermo
Fisher Scientific (Hampton, NH, USA). The cells were
fixed with 3.75% formaldehyde in PBS for 15 min at room
temperature. After three additional washes with PBS, the
plasma membrane was permeabilized with 0.1% Triton-
X-100, 10 mM Tris–HCl, pH 7.5, 120 mM sodium
chloride, 25 mM potassium chloride, 2 mM ethylene
glycol tetra-acetic acid (EGTA), and 2 mM EDTA for
10 min at room temperature. Slides were incubated with
3% bovine serum albumin (Sigma-Aldrich, St Louis,
MO, USA) before incubation with primary antibodies.
Rabbit anti-nucleostemin antibody and mouse anti-
MDM2 antibody was used at a 1:400 dilution. Second-
ary Alexa 488 anti-rabbit and Texas Red-conjugated
phalloidin were each used at 1:400 dilution. The images
were acquired and processed by M1/Hamamatsu Orca
(Hamamatsu City, Japan) and QImaging MicroPublisher
(Surrey, BC, Canada) color cameras.
In vivo tumor xenografts in NIH III nude mice
10AT-Her2 cells (3 × 105), 10AT-Neo cells (3 × 106), WT
elastase transfected 10AT-Her2 cells (3 × 105), Δ205 elas-
tase transfected 10AT-Her2 cells (3 × 105), or EV trans-
fected 10AT-Her2 cells (3 × 105) were mixed with an equal
volume of Matrigel (BD Biosciences, San Jose, CA, USA)
and inoculated subcutaneously into the mammary fat pad
region of NIH III mice as previously described [49]. I3C
was injected subcutaneously (300 mg/kg body mass) to
reduce the potential for formation of I3C condensation
products, such as the natural dimer DIM, that normally
occur in the acid conditions of the stomach. Stock solutions
of I3C (300 mM) were dissolved initially in DMSO and
then diluted in appropriate volume of PBS. Mice were also
palpated and tumor sizes were measured every other day
with calipers. Tumor volumes were calculated using the
following equation: V = a × b2/2, where a is the width and b
is the length of a tumor [86]. In the indicated experiments,
tumor xenografts were excised after the final day of I3C
treatments and visualized by light microscopy. Animal
experiments were done in accordance with the guidelines
of the Office of Laboratory Animal Care (approval ID:
OLAC/R116) and under the approval of the University of
California, Berkeley Animal Care and Use Committee.
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